In 2023, abemaciclib was allowed when used in adjuvant therapy with estrogen-modulating endocrine therapies, such as tamoxifen or aromatase inhibitors, for hormone receptor-positive, HER-2-negative, node-positive, early breast cancer that had a high likelihood of recurrence [10]. This evidence concerns the gene NR4A1 and breast carcinoma.